Presentations
Ploeger B., Ruigt G.S., Bom A., Houwing N., Iersel M.P.v. and Danhof M., PK-PD modelling of reversal of neuromuscular by a chemically optimised cyclodextrin. ASCPT.(2004).
Freijer J.I., Post T.M., Ploeger B.A., Jongh J.d. and Danhof M., Absorption model based on transport physics theory applied to Paracetamol. ASCPT.(2004).
Winter W.d., Jongh J.d., Moules I., Urquhart R., Eckland D. and Danhof M., Mechanistic Disease Progression Analysis Indicates that Pioglitazone Prevents the Progression of T2DM. ADA.(2004).
Liefaard C.L., Ploeger B.A., Molthoff C.F.M., Boellaard R., Lammertsma A.A., Danhof M. and Voskuyl R.A., Application of Population Pharmacokinetic Analysis for Quantification of in vivo Binding Properties in the Rat Brain by Positron Emission Tomography. PAGE.(2004). [Link to publication]
Winter W.d., Jongh J.d., Urquhart R., Moules I., Eckland D. and Danhof M., Mechanistic Disease Progression Analysis Indicates that Pioglitazone Impedes the Progression of Type 2 Diabetes Mellitus (T2DM) in Combination Therapy with Sulphonylurea and Metformin. EASD.(2004).
Winter W.d., Jongh J.d., and Danhof M., Integrating multiple biomarker into a single mechanistic model cascade of disease processes. cost b15.(2004).
Freijer J.I., Post T.M., Ploeger B., Jongh J.d. and Danhof M., Modelling of drug absorption as a transport proces limited. PAGE.(2003). [Link to publication]
Freijer J., Ploeger B., Jongh J.d. and Danhof M., Extrapolation of pharmacokinetics and toxicity from pre-clinical data to humans. PAGE.(2002). [Link to publication]
- « Previous
- 1
- …
- 10
- 11
- 12